Search Product
Structure Search
Search
Online Support
-
Customer service
Advantage Products
Location: Technique Support
Good reagent for hepatitis diagnosis: tetramethylbenzidine (TMB 54827-17-7) is the gospel of hepatitis patients
2014-08-11
来源：亚科官网
China is the world's largest population and the world's largest patient of hepatitis. China not only has a large number of hepatitis patients, but also a large number of hepatitis carriers. So it involves almost everyone's work and life, employment, school, military participation, etc. will have a hepatitis check. People with hepatitis or carriers are also often discriminated against by employment. Although it is repeatedly advocated not to discriminate against hepatitis patients or virus carriers, because people are born with fear of transmitting viruses, it will unnaturally exclude patients and their carriers. Therefore, early screening of hepatitis virus, early treatment has become the patient's biggest wish.
Early hepatitis screening methods are very backward. It is often necessary to wait 2-3 days for the diagnosis to produce results. After the 1980s, a new substrate, tetramethylbenzidine, referred to as TMB (cas 54827-17-7), was developed with Europe and the United States, and a new screening method based on enzyme-linked immunosorbent assay (ELISA) was developed. The new technology shortens the screening time of hepatitis to 30 min, and the method is convenient. Just take a little blood to test the rapid test.
In recent years, this technology has been further developed, from the early TMB two-component reagent to the TMB one-component reagent, making the hospital's laboratory screening personnel more convenient and efficient, and more efficient. The latest time-resolved fluorescence analysis method is also combined with the traditional ELISA analysis method, which further improves the timeliness and accuracy of the analysis results, which brings a good gospel to hepatitis patients.
Edited by Suzhou Yacoo Science Co., Ltd.
